NVS
Price
$132.30
Change
-$0.09 (-0.07%)
Updated
Oct 6, 04:59 PM (EDT)
Capitalization
255.52B
22 days until earnings call
SNY
Price
$49.71
Change
-$1.19 (-2.34%)
Updated
Oct 6, 04:59 PM (EDT)
Capitalization
124.01B
18 days until earnings call
Interact to see
Advertisement

NVS vs SNY

Header iconNVS vs SNY Comparison
Open Charts NVS vs SNYBanner chart's image
Novartis AG
Price$132.30
Change-$0.09 (-0.07%)
Volume$7.53K
Capitalization255.52B
Sanofi ADS
Price$49.71
Change-$1.19 (-2.34%)
Volume$81.54K
Capitalization124.01B
NVS vs SNY Comparison Chart in %
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. SNY commentary
Oct 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a StrongBuy and SNY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 07, 2025
Stock price -- (NVS: $132.39 vs. SNY: $50.90)
Brand notoriety: NVS and SNY are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 106% vs. SNY: 109%
Market capitalization -- NVS: $255.52B vs. SNY: $124.01B
NVS [@Pharmaceuticals: Major] is valued at $255.52B. SNY’s [@Pharmaceuticals: Major] market capitalization is $124.01B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $752.91B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $95.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 3 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).

  • NVS’s FA Score: 3 green, 2 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, NVS is a better buy in the long-term than SNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 4 bullish TA indicator(s).

  • NVS’s TA Score: 4 bullish, 4 bearish.
  • SNY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, NVS is a better buy in the short-term than SNY.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а +7.07% price change this week, while SNY (@Pharmaceuticals: Major) price change was +11.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.33%. For the same industry, the average monthly price growth was +2.27%, and the average quarterly price growth was +23.40%.

Reported Earning Dates

NVS is expected to report earnings on Oct 28, 2025.

SNY is expected to report earnings on Oct 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+4.33% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($256B) has a higher market cap than SNY($124B). NVS has higher P/E ratio than SNY: NVS (19.09) vs SNY (16.59). NVS YTD gains are higher at: 40.948 vs. SNY (10.213). NVS has higher annual earnings (EBITDA): 22.7B vs. SNY (12.6B). SNY has more cash in the bank: 15.4B vs. NVS (7B). SNY has less debt than NVS: SNY (22.3B) vs NVS (32.6B). NVS has higher revenues than SNY: NVS (55.2B) vs SNY (45.7B).
NVSSNYNVS / SNY
Capitalization256B124B206%
EBITDA22.7B12.6B180%
Gain YTD40.94810.213401%
P/E Ratio19.0916.59115%
Revenue55.2B45.7B121%
Total Cash7B15.4B45%
Total Debt32.6B22.3B146%
FUNDAMENTALS RATINGS
NVS vs SNY: Fundamental Ratings
NVS
SNY
OUTLOOK RATING
1..100
2190
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
4
Undervalued
PROFIT vs RISK RATING
1..100
1262
SMR RATING
1..100
2961
PRICE GROWTH RATING
1..100
4856
P/E GROWTH RATING
1..100
4891
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNY's Valuation (4) in the Pharmaceuticals Major industry is in the same range as NVS (16). This means that SNY’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (62). This means that NVS’s stock grew somewhat faster than SNY’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is in the same range as SNY (61). This means that NVS’s stock grew similarly to SNY’s over the last 12 months.

NVS's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as SNY (56). This means that NVS’s stock grew similarly to SNY’s over the last 12 months.

NVS's P/E Growth Rating (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (91). This means that NVS’s stock grew somewhat faster than SNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSSNY
RSI
ODDS (%)
Bearish Trend 4 days ago
38%
Bearish Trend 4 days ago
52%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
38%
Bearish Trend 4 days ago
40%
Momentum
ODDS (%)
Bullish Trend 4 days ago
44%
Bullish Trend 4 days ago
61%
MACD
ODDS (%)
Bullish Trend 4 days ago
61%
Bullish Trend 4 days ago
54%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
50%
Bullish Trend 4 days ago
54%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
46%
Bullish Trend 4 days ago
49%
Advances
ODDS (%)
Bullish Trend 6 days ago
50%
Bullish Trend 4 days ago
51%
Declines
ODDS (%)
Bearish Trend 19 days ago
45%
Bearish Trend 12 days ago
49%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
33%
Bearish Trend 4 days ago
40%
Aroon
ODDS (%)
Bullish Trend 4 days ago
43%
Bearish Trend 4 days ago
46%
View a ticker or compare two or three
Interact to see
Advertisement
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PHYS29.860.24
+0.81%
Sprott Physical Gold Trust
PPTY31.010.10
+0.31%
Vident U.S. Diversified Real Estate ETF
FIRI19.010.04
+0.24%
FIRE Funds Income Target ETF
SDG84.590.07
+0.09%
iShares MSCI Global Sust Dev Goals ETF
PAXS16.400.01
+0.06%
PIMCO Access Income Fund

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+1.08%
GSK - NVS
69%
Closely correlated
-0.78%
AZN - NVS
62%
Loosely correlated
+1.98%
PFE - NVS
60%
Loosely correlated
+1.07%
JNJ - NVS
55%
Loosely correlated
+1.43%
SNY - NVS
50%
Loosely correlated
+1.52%
More